Concordance of HPV genotype detection in cervical and urine samples among cervical cancer screen positive women
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243152Keywords:
Cervical cancer screening, Genotype distribution, HPV detection, Human papillomavirus, Urine samplesAbstract
Background: This study investigates the concordance of HPV genotype detection in urine and cervical samples among women undergoing cervical cancer screening.
Methods: Conducted over one year at the Department of Gynaecological Oncology, BSMMU, Dhaka, the study enrolled 74 women aged 30-60 years with positive visual inspection with acetic acid (VIA) results or abnormal Pap test findings. Urine samples (20 ml) and cervical samples were collected from each participant. The samples were analyzed using multiplex real-time PCR to amplify high-risk HPV types (16, 18, and others). DNA was extracted using the Qiagen viral DNA extraction kit. Sensitivity and specificity of HPV detection in urine samples were compared to cervical sampling, the gold standard. Data were analyzed with SPSS 22.0, and agreement was assessed using the Kappa index.
Results: In this study of 74 participants, HPV detection and genotype distributions were compared between cervical and urine samples. The mean age was 40.07 years, with 89.2% of participants being married and 75.7% multipara. There was moderate agreement between HPV detection in cervical and urine samples (Kendall’s tau = 0.752, p<0.001). Cervical samples identified a greater variety of HPV types, including HPV 16 and high-risk (HR) genotypes, compared to urine samples. The Cohen’s Kappa coefficient for agreement was 0.746 (p<0.001), indicating moderate concordance. Overall, cervical sampling demonstrated higher sensitivity for HPV detection.
Conclusions: The study demonstrates moderate concordance between cervical and urine samples in HPV detection, with cervical sampling showing higher sensitivity for identifying HPV genotypes.
Metrics
References
Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical HPV prevalence and type distribution in women with normal cytology in the European Union: a pooled analysis of 17 population-based studies. Int J Cancer. 2019;145(6):1585-91.
Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-24.
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long-term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337.
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65.
Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008;46(8):2595-604.
Alemany L, Saunier M, Alvarado-Cabrero I, Quiroz S, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98-107.
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1):198-207.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-301.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42.
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2007;90:1-636.
Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, et al. Prevalence of high-risk human papillomavirus genotypes and associated risk of cytologic abnormalities in cervical samples from 40,382 women in routine cervical cancer screening in the United States. Int J Cancer. 2015;136(5):1275-86.
Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73.
Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014;349.
Franceschi S, Rajkumar R, Snijders PJ, Arslan A, McKay-Chopin S, Ricciardi S, et al. Papillomavirus infection in rural women in southern India. Br J Cancer. 2014;110(2):411-7.
Leeman A, Delvenne P, Arbyn M, Dillner J, de Sanjosé S, Bogers J, et al. Human papillomavirus genotyping in urine: A review of the literature. J Clin Virol. 2019;114:12-21.
Stanczuk G, Currie H, Baxter G, Hayes S, Cuschieri K, Hibbitts S, et al. Phase 2 pilot study of the GenomEra HPV assay on the Nokia platform: analysis of the performance of self-collected and clinician-collected samples for HPV detection. Int J Cancer. 2017;140(7):1453-61.
Mbulawa ZZA, Marais DJ, Johnson LF, Coetzee D, Williamson AL. The impact of human papillomavirus vaccination on cervical cancer and related conditions: a review of evidence from South Africa. Vaccine. 2016;34(42):5022-9.
Tisci S, Shen YH, Fiedler V, Cantor SB, Cox DS, Kuo YF, et al. Cervical and vaginal cancer screening among women with human papillomavirus infection in the United States: a population-based study. Gynecol Oncol. 2018;148(1):57-63.
Vorsters A, Van Keer S, Biesmans S, Goossens H, Vanden Broeck D, Schuuring T, et al. HPV DNA detection in urine samples of women: Determinants and clinical value. Gynecol Oncol. 2014;133(1):202-8.
Louvanto K, Rintala MA, Syrjänen KJ, Grenman SE, Syrjänen SM. Genotype-specific human papillomavirus detection in self-collected vaginal and urine samples of women attending the cervical cancer screening programme: A pilot study. J Med Virol. 2019;91(4):783-90.
Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 2017;91(3):226-36.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2019;370(9590):890-907.
Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine. 2014;24(Suppl 3).